From HAE Egypt

Significant progress continued in Egypt throughout 2025 in the areas of hereditary angioedema (HAE) awareness, research, and clinical care.

In October 2025, Takeda Egypt hosted a major medical summit dedicated to improving care for people living with HAE. Held on 27 October, the meeting was described as a landmark event for the country, bringing together leading Egyptian and regional experts in the field. Discussions focused on the importance of early and accurate diagnosis, strengthening patient care pathways, and improving access to innovative therapies for this rare and often underdiagnosed condition. The summit reflected a growing national commitment to advancing HAE care in Egypt.

At the same time, a national multicenter observational study on HAE remained active during the fourth quarter of 2025. Titled A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt, the study involves centers in Al-Mansoura, Alexandria, and Cairo. Trial records were updated on 20 October 2025, confirming the ongoing nature of this important research effort, which aims to provide real-world insights into how HAE is currently diagnosed and managed across different regions of the country.

Awareness-raising efforts also continued throughout much of 2025. The Mersal Foundation, an Egyptian NGO and member of the National Alliance for Civil Development Work, led a national campaign titled “وذمة مش أزمة” (“Edema, Not a Crisis”). Launched on 6 January 2025, the campaign remained active through at least the first nine months of the year. Its messaging emphasized that effective treatments for HAE are now available in Egypt, while highlighting underdiagnosis as a persistent challenge. The campaign placed strong focus on educating physicians to consider HAE in patients with recurrent, unexplained swelling and encouraged family screening when one member is diagnosed, given the hereditary nature of the disease.

In a further milestone for HAE care in Egypt, the Food & Drug Allergy Center has been officially designated as the country’s first ACARE (Angioedema Center of Reference and Excellence). A copy of the certification has been provided, marking an important step forward in the development of specialized HAE services nationwide.